| 000 | 01266 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250513054205.0 | ||
| 264 | 0 | _c19950126 | |
| 008 | 199501s 0 0 eng d | ||
| 022 | _a0749-0704 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCrippen, D W | |
| 245 | 0 | 0 |
_aPharmacologic treatment of brain failure and delirium. _h[electronic resource] |
| 260 |
_bCritical care clinics _cOct 1994 |
||
| 300 |
_a733-66 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnalgesics _xtherapeutic use |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBrain Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aCritical Illness _xtherapy |
| 650 | 0 | 4 |
_aDelirium _xdrug therapy |
| 650 | 0 | 4 |
_aDopamine _xmetabolism |
| 650 | 0 | 4 |
_aHemodynamics _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypnotics and Sedatives _xtherapeutic use |
| 650 | 0 | 4 | _aMonitoring, Physiologic |
| 650 | 0 | 4 |
_aNarcotic Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aNeurotransmitter Agents _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aNorepinephrine _xmetabolism |
| 650 | 0 | 4 |
_aPsychomotor Agitation _xprevention & control |
| 650 | 0 | 4 |
_aSubstance Withdrawal Syndrome _xprevention & control |
| 773 | 0 |
_tCritical care clinics _gvol. 10 _gno. 4 _gp. 733-66 |
|
| 999 |
_c8000252 _d8000252 |
||